Healthtech Late Stage Investors & VC Firms
847 firms in this list, with a median first check of $1M. 197 of them lead rounds. Generated from verified public data and updated continuously.
Nippon Mirai Capital Co. Ltd.
TokyoGrowth–Late Stage
North Forge Technology Exchange
WinnipegPre-Seed–Late Stage
Northwestern Ontario Innovation Centre
Thunder BayPre-Seed–Late Stage
Pura Vida Investments
New YorkLate Stage
RKCA
CincinnatiPre-Seed–Late Stage
SCP
Hong KongSeed–Late Stage
Sheares Healthcare Group
SingaporeSeed–Late Stage
Shiyu Capital
HainanSeed–Late Stage
SightLine Partners
BloomingtonLate Stage
Soleus Capital
GreenwichLate Stage
Symphony International Holdings
Growth–Late Stage$15M – $100M
3 people
Veddis
LondonSeed–Late Stage
Mitsui Sumitomo Insurance Capital
TokyoPre-Seed–Late Stage$1.1M – $198M
1 person
Alibaba Entrepreneurs Fund
Hong KongSeed–Late Stage$1.2M – $150M
2 people
Redpoint Ace Ventures
ShanghaiSeed–Late Stage
5 people
Hiventures
BudapestSeed–Late Stage$43.2K – $43.2M
2 people
Longbow Capital LLP
NorwichSeries C–Late Stage$1.3M – $12.7M
2 people
Nissay Capital
TokyoPre-Seed–Late Stage$610K – $71M
1 person
Annox Capital
BirminghamSeed–Late Stage$100K – $30M
1 person
Cutlass Capital, L.L.C.
BostonSeed–Late Stage$3M – $7M
1 person
FFG Venture Business Partners
FukuokaPre-Seed–Late Stage$1M – $50M
1 person
Japan Asia Investment
TokyoPre-Seed–Late Stage$1M – $10M
1 person
BioTrack Capital
Grand CaymanSeed–Late Stage
4 people
Holtzbrinck Digital GmbH
MunichSeries A–Late Stage
4 people
Related lists
Healthtech Investors & VC Firms (3208)Late Stage Investors & VC Firms (2864)Healthtech Seed Investors & VC Firms (2488)Healthtech Series A Investors & VC Firms (2210)Healthtech Investors & VC Firms in United States (1616)Healthtech Pre-Seed Investors & VC Firms (1328)Healthtech Series B Investors & VC Firms (1216)Healthtech Growth Investors & VC Firms (1213)Late Stage Investors & VC Firms in United States (1101)Late Stage Investors & VC Firms in Global (857)
Data sourced from public filings and firms' own websites — see our methodology.